{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T06:30:17Z","timestamp":1793773817797,"version":"4.6.1"},"reference-count":29,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"vor","delay-in-days":18,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:label\/>\n                    <jats:p>Little is known about the survival benefit of relmacabtagene autoleucel (relma\u2010cel) in the current therapeutic landscape of relapsed\/refractory (r\/r) follicular lymphoma (FL). The current study compared the survival outcomes of Chinese FL patients administered relma\u2010cel in RELIANCE (NCT04089215) and usual care in a retrospective, observational, large\u2010scale real\u2010world study (RWS). An indirect treatment comparison was carried out for 27 patients from RELIANCE and 53 patients from the RWS in China. Additionally, a direct comparison was made with the SCHOLAR\u20105 study, which assessed available treatment options abroad. After propensity score matching, disease status (FLIPI2 score, histological grade, relapse status, POD24) in the relma\u2010cel group appeared to indicate more severe disease versus the usual care group. Nevertheless, median progression\u2010free survival (PFS) was not reached (95% CI 8.97\u2010NR) for relma\u2010cel versus 19.98\u00a0months (95% CI 16.03\u201328.98) for usual care, indicating a hazard ratio (HR) of 0.40 (95% CI 0.13\u20131.23). Besides, a comparative analysis of RELIANCE and SCHOLAR\u20105, applying available treatment options abroad, revealed an HR for PFS of 0.20 (95% CI 0.07\u20130.58). At 24\u00a0months, 100% of patients survived after relma\u2010cel infusion, versus 38.2% after usual care in China and 62.7% after usual care treatment in SCHOLAR\u20105, respectively. Relma\u2010cel exhibits superior survival benefits versus current conventional therapies in r\/r FL patients after \u2265 2 treatment lines.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/hon.70051","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T05:47:17Z","timestamp":1742363237000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Survival Benefit of Relmacabtagene Autoleucel Versus Usual Care in Relapsed\/Refractory Follicular Lymphoma: A Matching\u2010Adjusted Indirect Analysis"],"prefix":"10.1002","volume":"43","author":[{"given":"Fenghua","family":"Gao","sequence":"first","affiliation":[{"name":"Department of Lymphoma and National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine Tianjin Medical University Cancer Institute and Hospital National Clinical Research Center for Cancer Tianjin's Clinical Research Center for Cancer Key Laboratory of Cancer Prevention and Therapy the Sino\u2010US Center for Lymphoma and Leukemia Research  Tianjin China"},{"name":"Department of Hematology the Affiliated Cancer Hospital of Zhengzhou University &amp; Henan Cancer Hospital  Zhengzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine Tianjin Medical University Cancer Institute and Hospital National Clinical Research Center for Cancer Tianjin's Clinical Research Center for Cancer Key Laboratory of Cancer Prevention and Therapy the Sino\u2010US Center for Lymphoma and Leukemia Research  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine Tianjin Medical University Cancer Institute and Hospital National Clinical Research Center for Cancer Tianjin's Clinical Research Center for Cancer Key Laboratory of Cancer Prevention and Therapy the Sino\u2010US Center for Lymphoma and Leukemia Research  Tianjin China"},{"name":"Department of Hematology Cangzhou Central Hospital  Cangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwei","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine Tianjin Medical University Cancer Institute and Hospital National Clinical Research Center for Cancer Tianjin's Clinical Research Center for Cancer Key Laboratory of Cancer Prevention and Therapy the Sino\u2010US Center for Lymphoma and Leukemia Research  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"He","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine Tianjin Medical University Cancer Institute and Hospital National Clinical Research Center for Cancer Tianjin's Clinical Research Center for Cancer Key Laboratory of Cancer Prevention and Therapy the Sino\u2010US Center for Lymphoma and Leukemia Research  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangrui","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine Tianjin Medical University Cancer Institute and Hospital National Clinical Research Center for Cancer Tianjin's Clinical Research Center for Cancer Key Laboratory of Cancer Prevention and Therapy the Sino\u2010US Center for Lymphoma and Leukemia Research  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine Tianjin Medical University Cancer Institute and Hospital National Clinical Research Center for Cancer Tianjin's Clinical Research Center for Cancer Key Laboratory of Cancer Prevention and Therapy the Sino\u2010US Center for Lymphoma and Leukemia Research  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine Tianjin Medical University Cancer Institute and Hospital National Clinical Research Center for Cancer Tianjin's Clinical Research Center for Cancer Key Laboratory of Cancer Prevention and Therapy the Sino\u2010US Center for Lymphoma and Leukemia Research  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanfang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine Tianjin Medical University Cancer Institute and Hospital National Clinical Research Center for Cancer Tianjin's Clinical Research Center for Cancer Key Laboratory of Cancer Prevention and Therapy the Sino\u2010US Center for Lymphoma and Leukemia Research  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine Tianjin Medical University Cancer Institute and Hospital National Clinical Research Center for Cancer Tianjin's Clinical Research Center for Cancer Key Laboratory of Cancer Prevention and Therapy the Sino\u2010US Center for Lymphoma and Leukemia Research  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengzi","family":"Qian","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine Tianjin Medical University Cancer Institute and Hospital National Clinical Research Center for Cancer Tianjin's Clinical Research Center for Cancer Key Laboratory of Cancer Prevention and Therapy the Sino\u2010US Center for Lymphoma and Leukemia Research  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyong","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine Tianjin Medical University Cancer Institute and Hospital National Clinical Research Center for Cancer Tianjin's Clinical Research Center for Cancer Key Laboratory of Cancer Prevention and Therapy the Sino\u2010US Center for Lymphoma and Leukemia Research  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Xia","sequence":"additional","affiliation":[{"name":"JW Therapeutics (Shanghai) Co. Ltd  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su","family":"Yang","sequence":"additional","affiliation":[{"name":"JW Therapeutics (Shanghai) Co. Ltd  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zisong","family":"Zhou","sequence":"additional","affiliation":[{"name":"JW Therapeutics (Shanghai) Co. Ltd  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Tian","sequence":"additional","affiliation":[{"name":"JW Therapeutics (Shanghai) Co. Ltd  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Qin","sequence":"additional","affiliation":[{"name":"JW Therapeutics (Shanghai) Co. Ltd  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8742-4348","authenticated-orcid":false,"given":"Xianhuo","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine Tianjin Medical University Cancer Institute and Hospital National Clinical Research Center for Cancer Tianjin's Clinical Research Center for Cancer Key Laboratory of Cancer Prevention and Therapy the Sino\u2010US Center for Lymphoma and Leukemia Research  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilai","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine Tianjin Medical University Cancer Institute and Hospital National Clinical Research Center for Cancer Tianjin's Clinical Research Center for Cancer Key Laboratory of Cancer Prevention and Therapy the Sino\u2010US Center for Lymphoma and Leukemia Research  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,3,19]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010022\u201001620\u20102"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2020.02.001"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.59.7534"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3138"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15708"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.008"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25696"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1708566"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(18)30864\u20107"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2022.100992"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095\u20103941.2022.0585"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26711"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.863021"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014375"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12874\u2010021\u201001308\u20108"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572\u2010019\u20100132\u2010x"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.4786"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.46.9718"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102007\u201010\u2010117671"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.19.9117"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq027"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102006\u201005\u2010021113"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2019.1663169"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2007.12.5070"},{"issue":"23","key":"e_1_2_11_26_1","first-page":"2628","article-title":"Venetoclax\u2010Rituximab With or Without Bendamustine vs Bendamustine\u2010Rituximab in Relapsed\/refractory Follicular Lymphoma","volume":"136","author":"Zinzani P. L.","year":"2020","journal-title":"Blood"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22617"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.084723"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102003\u201004\u20101205"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1264723"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.70051","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T07:54:22Z","timestamp":1755503662000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.70051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1002\/hon.70051"],"URL":"https:\/\/doi.org\/10.1002\/hon.70051","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1002\/HON.70051\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.70051\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.70051\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.70051\/v2\/decision1","asserted-by":"object"}]},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"2024-11-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70051"}}